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Somatic frameshift mutations in some genes containing
coding mononucleotide repeats (cMNRs) are well known
characteristics of tumors with high microsatellite
instability (MSI-H). We identified 22 novel and 11
known target genes containing cMNRs with a length of
10 or more nucleotides by using a systematic database
search. Frameshift mutation analysis was performed with
these 33 genes in 39 MSI-H and 24 microsatellite stable
(MSS) colorectal carcinomas by assessing the mobility
shifts of PCR products in gel electrophoresis and by
sequencing. All the 39 MSI-H colorectal carcinomas,
except one, showed mutations in more than one gene,
while no mutations were found in 24 MSS colorectal
carcinomas. Of these MSI-H tumors, 11 genes were
mutated in more than 40%. The most frequently mutated
novel genes were MARCKS (72%), FLJ11383 (74%)
and TAF1B (82%). Biallelic inactivation in MARCKS
and FLJ11383 was also frequent in MSI-H tumors. The
observed mutation frequency of the 11 known target
genes was compatible with that found by previous
studies. The very high frequency of mutations, biallelic
mutations and the predicted truncation of protein
products suggests that mutations of MARCKS,
FLJ11383 and TAF1B are selected, and play a role in
the tumorigenesis of MSI-H colorectal carcinomas.
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Introduction
The mismatch repair (MMR) system plays an important
role in reducing mutations and maintaining genomic
instability. In tumors with inactivation of one of the
MMR genes, the heteroduplex DNA formed due to
slippage-induced replication errors in the repetitive
sequences is not corrected, and this gives rise to
insertions and deletions of repeat units after subsequent
replication (Strand et al., 1993). Such alterations usually
occur in microsatellites, which are tandem repeats of
oligonucleotide units that are found dispersed through-
out the entire genome. Alterations in size of these
microsatellite DNA sequences, termed microsatellite
instability (MSI), has been observed in most tumors of
hereditary nonpolyposis colorectal cancer (HNPCC)
syndrome and also in some types of sporadic carcino-
mas (Perucho, 1996; Eshleman and Markowitz, 1996).
Although MSI has been usually demonstrated in the
noncoding portion of genes, it has also been recently
identified in the protein coding regions of some cancer-
related genes, and in some of the DNA repair genes
(Markowitz et al., 1995; Malkhosyan et al., 1996). MSI
in the coding region of these genes may cause
accumulation of truncated protein and loss of gene
function. Many genes have been identified to have
coding mononucleotide repeats (cMNRs) and in several
genes, mutations in cMNRs have been reported (Souza
et al., 1996; Rampino et al., 1997; Yamamoto et al.,
1997; Duval et al., 1999; Kim et al., 2001; Bader et al.,
1999; Schwartz et al., 1999). Genes bearing a high rate
of mutation, biallelic inactivation and functional
evidence of tumor suppressor are believed to be
candidate target genes in high microsatellite instability
(MSI-H) tumors (Boland et al., 1998). Other genes
containing cMNRs with low mutational frequencies are
not regarded as target genes. Mutations of the target
genes appear to accumulate and to be selected during
tumor progression in MSI-H tumors. Mutations are
more frequently found in MSI-H carcinomas than in
MSI-H adenomas, and mutations of the transforming
growth factor beta type II receptor (TGF-b RII) and the
TCF-4 genes are strongly selected in gastrointestinal
malignancies, but not in endometrial cancer (Duval et
al., 1999; Kim et al., 1999).
Although there has been a tremendous increase in
the reported number of candidate target genes in MSI-
H tumors, many additional genes containing cMNR
sequences and frequent mutations in these regions can
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be identified by a human genome-wide systematic data
base search and by a mutational analysis of MSI-H
tumors. Currently, three studies are available, and
these studies reported several additional candidate
target genes (Woerner et al., 2001; Mori et al., 2001;
Park et al., 2002). In the present study, we searched a
number of genes containing cMNR with a length of 10
or more nucleotides, and analysed frameshift mutations
in these repetitive sequences in our 39 MSI-H color-
ectal carcinomas and eight MMR-deficient cell lines.
We found that MARCKS, FLJ11383 and TAF1B
contain cMNRs, which are also characterized by high
mutational frequencies and biallelic mutations, and are
thus likely to be additional target genes in MSI-H
tumors.
Results
Database search for coding sequences with MNR and
confirmation of novel cMNRs
Our database search identified a total of 4071 coding
sequences containing MNR with a length of seven or
more nucleotides (2248 for A, 690 for T, 369 for G and
764 for C). Among these coding sequences, 102
contained MNR sequences with a length of 10 or
more nucleotides (56 for A, 38 for T, five for G and
three for C).
Confirmation and selection of candidate target genes
containing cMNRs
We selected genes with cMNRs for this experiment
based on the following two factors: (a) that the cMNR
sequence was confirmed in both the genomic DNA
database and the EST database; (b) that variability of
the cMNR was present exclusively in the MSI-H
tumors and in the MMR-deficient cell lines, and not
present in matched normal mucosa, MSS tumors and
MMR-proficient cell lines. Since our preliminary
experiments and other studies had demonstrated that
the number of nucleotides in the MNR was related to
the high mutational frequency (Parsons et al., 1995),
we chose 102 coding sequences containing MNRs with
a length of 10 or more nucleotides. After manually
inspecting the alignments with human genomic
sequence data and other sequence analysis results, 33
full-length cDNA sequences were finally verified to
have cMNRs with a length of 10 or more nucleotides.
In the finally selected 33 genes, five genes (TAF1B,
MARCKS, FLJ11186, KIAA1052 and FLJ13615)
contained (A)11. Of the remaining 28 genes, 27
contained (A)10 and one contained (T)10 in their
coding regions (Table 1). These sequences encompassed
all of the previously identified 11 candidate target genes
(TGF-b RII, AIM2, SEC63, Caspase 5, OGT, ATR,
MBD4, SYCP1, GART, PRKDC and MAC30) in MSI-
H tumors (Markowitz et al., 1995; Bader et al., 1999;
Schwartz et al., 1999; Woerner et al., 2001; Mori et al.,
2001), the remaining 22 genes had not been identified
before.
Frequency of frameshift mutations of genes containing
cMNRs
We analysed frameshift mutations of these selected
cMNRs in eight MMR-deficient cell lines and 39
MSI-H colorectal cancers. Paired samples of normal
mucosal tissue from 39 MSI-H colorectal cancers,
paired samples of cancer and normal mucosal tissue
from 24 MSS colorectal cancers, and three MMR-
proficient cell lines were used as control. All the 39
MSI-H colorectal carcinomas, except one, showed
mutations in more than one gene, while no mutations
were found in 24 MSS colorectal carcinomas.
Examples of frameshift mutations are shown in
Figures 1 and 2. Mutational rates of MSI-H colorectal
carcinomas are summarized in Figure 3. Among the
33 genes evaluated, frequent frameshift mutations
(440%) in MSI-H colorectal carcinomas were found
in 11 genes (Figure 3). Five of these 11 genes, TGF-b
RII, AIM2, SEC63, Caspase 5 and OGT have been
previously reported to show frameshift mutations
(Markowitz et al., 1995; Schwartz et al., 1999;
Woerner et al., 2001; Mori et al., 2001), but the
other six genes had not been evaluated before. The
mutational frequencies of the five known genes in our
MSI-H colorectal carcinomas were 85% in TGF-b
RII, 67% in AIM2, 56% in SEC63, 49% in Caspase 5
and 41% in OGT. These mutational incidences are
similar to those previously reported. Among the six
genes that were not reported previously as candidate
target genes in MSI-H tumors, MARCKS (72%),
FLJ11383 (74%) and TAF1B (82%) showed frequent
mutations in MSI-H colorectal carcinomas. The
mutational rates of the eight MMR-deficient cell lines
were generally similar to those of the MSI-H color-
ectal cancers.
We differentiated between monoallelic and biallelic
status of the mutations by comparing the intensities of
the normal and abnormal (shifted) bands. The
percentage of tumor cells, determined on histological
slides after cryostat fractionation, amounted to
approximately 70 – 90%. Biallelic mutations were
evaluated after taking the percentage of tumor cells
into account. Of the 33 genes evaluated, 23 showed
biallelic mutations in MSI-H colorectal carcinomas
and/or MMR-deficient cell lines. In the four genes with
mutational frequencies exceeding 70%, biallelic muta-
tions were frequent in MARCKS (25.6%), FLJ111383
(30.8%) and TGF-b RII (51.3%) but rare in TAF1B
(2.6%).
Discussion
Our systematic approach to the identification of
candidate target genes in MMR-deficient tumors
enabled us to identify many novel genes. We found
many genes containing cMNR sequences in their
coding region and identified very frequent frameshift
mutations at the cMNRs in MARCKS, FLJ11383 and
TAF1B in our MSI-H colorectal carcinomas.
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Frequent nucleotide insertions and/or deletions in
the MNRs are well known in MMR-deficient tumors.
Mutations in MNRs have been reported in both coding
and non-coding regions with variable frequencies (Mori
et al., 2001; Parsons et al., 1995; Zhang et al., 2001). In
this study, we chose candidate genes containing
cMNRs with a length of 10 or more nucleotides,
because the number of nucleotides in the MNR have
been reported to be related to increased mutational
frequency (Chen et al., 1995; Eichler et al., 1994; Tran
et al., 1997). We found an average mutational
frequency of 55% in the five genes containing 11
nucleotides in cMNRs and an average mutational
frequency of 31% in genes containing cMNRs with a
length of 10 nucleotides. These mutational frequencies
are very high compared to those previously reported
for target genes, which suggests that many of them are
potentially important target genes. Among these genes,
MARCKS, FLJ11383 and TAF1B seem to be most
noteworthy as they bear mutational incidences similar
to that of the most well known important target gene
Table 1 List and description of genes analysed
GenBank Type of Chromosomal
accession number Gene description Gene name repeat location
D50683 Transforming growth factor, beta receptor II TGF-b RII A(10) 3p22
L39061 TATA box binding protein (TBP)-associated TAF-1B A(11) 2p25
factor, RNA polymerase I, B, 63 kD
NM_024938 FLJ11383 A(10) 1
NM_002356 Myristoylated alanine-rich protein kinase C MARCKS A(11) 6q22.2
substrate
NM_004833 Absent in melanoma 2 AIM2 A(10) 1q22
NM_018353 FLJ11186 A(11) 14q13.1 – 14q21.3
NM_007214 Endoplasmic reticulum translocon component SEC63 A(10) 6q16 – 22
(S. cerevisiae) like
NM_004347 Apoptosis-related cysteine protease Caspase 5 A(10) 11q22.2 – q22.3
NM_003201 Transcription factor 6-like 1 (mitochondrial TCF6L1 A(10) 7pter-cen
transcription factor 1-like
AB040903 KIAA1470 A(10) 1
NM_003605 O-linked N-acetylglucosamine (GlcNAc) OGT T(10) X
transferase (UDP-N-acetylglucosamine:
polypeptide-N-acetylglucosaminyl transferase)
NM_003369 UV radiation resistance associated gene UVRAG A(10) 11q13.5
NM_014956 KIAA1052 protein A(11) 11
NM_006846 Serine protease inhibitor Kazal type 5 SPINK5 A(10) 5q32
NM_017685 FLJ20139 A(10) 1
NM_001184 Ataxia telangiectasia and Rad3 related ATR A(10) 3q22 – 24
NM_018365 FLJ11222 A(10) 15q11.2
NM_025114 FLJ13615 A(11) 12
NM_003925 Methyl-CpG binding domain protein 4 MBD4 A(10) 3q21 – 22
NM_003176 Synaptonemal complex protein 1 SYCP1 A(10) 1p13 – 12
NM_001090 ATP-binding cassette, sub-family F (GCN20), ABCF1 A(10) 6p21.33
member 1
NM_018979 Protein kinase; lysine deficient 1 PRKWNK1 A(10) 12p13.3
AB033094 KIAA1268 A(10) 3
NM_002915 Replication factor C (acitvator 1) 3 (38 kD) RFC3 A(10) 13q12.3 – q13
NM_000819 Phosphoribosylglycinamide formyltransferase, GART A(10) 21q22.11
phosphoribosylglycinamide synthetase,
phosphoribosylaminoimidazole synthetase
AB037754 FLJ20333 (KIAA1333) A(10) 14
AL136680 DKFZp564C2478 A(10) 1
U47077 Protein kinase, DNA-activated, catalytic PRKDC A(10) 8q11
polypeptide
NM_024570 FLJ11712 A(10) 3
NM_001271 Chromodomain helicase DNA binding protein 2 CHD2 A(10) 15q26
AL096857 KIAA1096 A(10) 1
L19183 Differentially expressed in neuroblastoma A(10) 17q11.2
(MAC30)
AL008635 High-mobility group protein 2-like 1 HMG2L1 A(10) 22q13.1
Figure 1 Alteration of the cMNR number of the MARCKS,
FLJ11383 and TAF1B genes in MSI-H colorectal carcinomas.
N, DNA from normal mucosal tissue; T, DNA from carcinoma
tissue. Lanes 1 – 20 contain PCR products derived from paired tis-
sues of MSI-H colorectal carcinomas. Lanes 21 – 31 contain PCR
products derived from the cell lines. LS-174T, HCT-8, NCI-H747,
SNU-C2A, SNU-C4, DLD-1, HCT-116 and LOVO cell lines are
MMR-deficient and the remaining three cell lines are MMR-pro-
ficient
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of MSI-H tumors, TGF-b RII. Moreover, we
confirmed the expressions of wild and mutant forms
of MARCKS, FLJ11383 and TAF1B transcripts in our
MSI-H colorectal tumors and of wild forms in matched
normal mucosal tissues by RT-PCR analysis (data not
shown).
One of the most important significances of these
frameshift mutations in cMNR is the functional
inactivation of the genes. Mutation in the cMNR of
one allele and its inactivation in other allele by a
different mechanism (i.e., mutations in a non-MNR
tract, deletion or methylation inactivation) provides
another possible explanation for its complete func-
tional inactivation. The biallelic inactivation of the
TGF-b RII gene through mutation in MNR or non-
MNR has been reported (Markowitz et al., 1995;
Parsons et al., 1995). In this study, we found biallelic
mutations of the cMNR in our MSI-H colorectal
carcinomas in 17 of 33 genes, and these were most
frequent in TGF-b RII, FLJ11383 and MARCKS.
These findings also support the notion that frameshift
mutations of these three novel target genes are directly
related to functional inactivation and might be related
to the tumorigenesis of the MSI-H colorectal carcino-
mas. Further analysis of the functional inactivation of
these genes, and confirmation of their roles in the
tumor initiation, and/or progression is necessary to
prove that these newly identified genes are important
target genes in MSI-H tumors.
A review of the literature regarding the novel
candidate target genes of MSI-H tumors suggests that
MARCKS is potentially important in cell proliferation
and/or differentiation. MARCKS (myristoylated
alanine-rich protein kinase C substrate; alternate
symbols are MACS and 80K-L) is one of the most
prominent intracellular substrates for PKC and is
abundant and widely distributed in almost all cell
types that have been investigated (Blackshear, 1993).
The role of MARCKS in the regulation of cell
proliferation has been suggested. Moreover, it has
been reported that MARCKS concentrations are
attenuated in several transformed cell lines (Brooks et
al., 1996; Manenti et al., 1998). This downregulation of
MARCKS during proliferation appears to occur via
both PKC-dependent and -independent pathways
(Brooks et al., 1992). The level of MARCKS is low
Figure 2 Nucleotide sequence analysis of the representative
clones of MARCKS, FLJ11383 and TAF1B from MSI-H colorec-
tal carcinomas. Arrowheads pointing up or down indicate inser-
tions or deletions of one nucleotide in the polydeoxyadenosine
repeats, respectively. WT denotes wild type
Figure 3 Frequency of frameshift mutations in 33 genes in 39 MSI-H colorectal carcinomas (dark bars) and eight MMR-deficient
cell lines (empty bars). Four genes, TGFb-RII, TAF1B, FLJ11383 and MARCKS, showed mutational rates of greater than 70% in
MSI-H colorectal carcinomas
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in some cell lines when they are actively proliferating,
however, it sharply increases again when they stop
dividing (Herget et al., 1993). Furthermore, the over-
expression of MARCKS strongly suppresses the
proliferation of human tumor-derived choroidal mela-
noma cells (Manenti et al., 1998). The (A)11 repeat in
MARCKS is located in exon 2. Frameshift mutations
affecting (A)11 cMNR will lead to truncation of the
protein in the effector domain, thereby eliminating its
functional activity. Therefore, it is tempting to
speculate that the inactivation of MARCKS is
associated with tumorigenesis.
Although the incidences of frameshift mutations
were very high, the role of mutations of TAF1B and
FLJ11383 in tumorigenesis is not as clear as that of
MARCKS. This is principally due to the fact that
these two genes have not been reported to have any
function related to tumorigenesis. TAF1B (TAFI63) is
the second largest subunit of the TATA box-binding
protein (TBP)-containing promoter selectivity factor
TIF-1B/SL1 (Comai et al., 1994), and TAF1B is
known to be related to ribosomal transcription,
however, no definite role for TAF1B in cell prolifera-
tion and/or differentiation had been identified. The
(A)11 repeat of TAF1B is located in exon 3 and the
expected truncated proteins of one bp deleted and two
bp deleted transcripts are approximately Mr 10 235
and Mr 7 793 in size respectively, as opposed to the
Mr 60 873 of the normal TAF1B protein. Therefore,
the truncated protein is expected to be in its inactive
form. Most of the inactivation of TAF1B is presumed
to be haplo-insucient instead of completely insu-
cient, because biallelic mutations were rare in TAF1B.
The significance of the haplo-insuciency of target
genes in the tumorigenesis of MSI-H tumors had been
proposed previously (Schwartz et al., 1999; Ohmiya et
al., 2001). In the case of the FLJ11383 gene, no
known function has yet been reported. At present two
kinds of FLJ11383 transcripts have been reported, a
long form of 2205 bp (GeneBank accession number
BC008300) and a smaller form of 1833 bp (GeneBank
accession number NM_024938). The (A)10 repeat is
only present in the smaller form, and this repeat is
located close to the carboxyl terminal (codons 267 –
270 of 286 amino acids). We confirmed the expres-
sions of wild and mutant forms of the smaller
FLJ11383 transcripts in our MSI-H colorectal tumors
and matched normal mucosal tissues by RT –PCR
analysis (data not shown). Although the role of
FLJ11383 mutations in tumorigenesis remains enig-
matic, frequent frameshift mutations and biallelic
mutations in MSI-H tumors suggest that FLJ11383
might be a potentially important target in MSI-H
colorectal carcinomas, and that it requires further
functional study.
In conclusion, we found many novel genes contain-
ing cMNRs with a length of 10 or more nucleotides
and identified a high frequency of frameshift mutations
in MARCKS, FLJ11383 and TAF1B genes in MSI-H
colorectal carcinomas. Further functional study of
these target genes will extend our understanding of
the molecular pathways of MSI-H tumors and enable
novel diagnostic and therapeutic approaches.
Materials and methods
Identification of cMNR
In order to extract genome-wide cMNRs, we scanned the
Hs.seq.uniq file (ftp://ncbi.nlm.nih.gov/repository/UniGene),
which contains the representative sequences and annotations
from each cluster in the human UniGene database (Build
138, February 2001), by using a locally developed computer
program (named Exact Tandem Repeats Finder) by one of
the authors (H Rhee). After searching the annotated coding
sequence with cMNRs, we verified these sequences by
comparing alignments with those of the human genomic
sequence data at the LocusLink website (http://ncbi.nlm.nih.
gov/LocusLink). Among the initially selected coding
sequences with mononucleotide repeats (MNRs), sequences
containing MNRs in the non-coding region, sequences with
unknown genomic DNA sequence, sequences showing
polymorphism at repetitive sites, those showing discrepancies
with the corresponding genomic DNA sequences, and
pseudogenes were excluded from this experiment.
Through this extensive systematic analysis, 33 coding
sequences containing MNRs with a length of 10 or more
nucleotides were finally selected for mutation data analysis.
GeneBank accession numbers, descriptions and names are
described in Table 1. Of the 33 genes, 20 genes had some
known functions.
Tissue selection and cell lines
In total, 39 cases, confirmed as MSI-H colorectal carcinomas,
and 24 cases of microsatellite stable (MSS) colorectal
carcinomas were included in this study. Most of the cases
had been previously analysed for MSI status (Kim et al.,
2001). In each case, grossly normal mucosa remote from the
tumor was included as a control. All of the cases were
identified consecutively for the Gastrointestinal Tumor
Working Group Tissue Bank at Yonsei University Medical
Center (Seoul, Korea) between December 1996 and Novem-
ber 1999. DNAs were extracted from fresh frozen tissues.
Tumor specimens were microdissected on a cryostat and
fractionated to enrich the tumor cell population.
Eleven cell lines were obtained from the American Type
Culture Collection (ATCC; http://www.atcc.org) and from
the Korean Cell Line Bank (KCLB; http://cellbank.
snu.ac.kr). Eight (LS-174T, HCT-8, NCI-H747, SNU-C2A,
SNU-C4, DLD-1, HCT-116 and LOVO) were MMR-
deficient and three (NCI-H508, SW-480 and HT-29) were
MMR-proficient in terms of their MSI status, as determined
by a previous study (Ku et al., 1999; Choi et al., 1998;
Lengauer et al., 1997; Park et al., 1987). We confirmed the
presence of MSI by using BAT26 and BAT25 markers. Cells
were grown in RPMI supplemented with 10% FBS (Life
Technologies, Inc., Grand Island, NY, USA), penicillin and
streptomycin at 378C in 5% CO2.
Frameshift mutation analysis and sequencing
Frameshift mutations in the cMNRs were analysed using a
PCR-based assay using the primers described in Table 2.
PCR reactions were carried out in a 20 ml mixture containing
1.5 mM MgCl2, 20 pmol primer, 0.2 mM of each dATP,
dGTP, dTTP, 5 mM dCTP, 1 mCi of [a-32P]-dCTP (3000 Ci/
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mmol; NEN DuPont, Boston, MA, USA), 50 ng of sample
DNA, 16PCR buffer and 1.25 U Taq DNA polymerase
(Life Technologies, Inc.) using the following conditions; an
initial denaturation at 958C for 5 min, followed by DNA
amplification for 25 – 30 cycles of denaturation at 958C for
30 s, primer annealing at 55 – 608C for 30 s, and primer
extension at 728C for 15 s. PCR products were separated in
6% polyacrylamide gels containing 5.6 M urea, followed by
autoradiography. Frameshift mutations at cMNR sequences
were scored according to the mobility shifts of PCR products.
In order to confirm that a shifted band represented a
frameshift mutation, genomic DNA fragments exhibiting
bandshifts of MARCKS, FLJ11383 and TAF1B were excised,
eluted from the polyacrylamide gel, and subcloned to
pT7Blue vector (Novagen, Madison, WI, USA). Plasmids
were sequenced using a T7 sequencing kit (USB, Cleveland,
OH, USA) and separated in 8% denaturing polyacrylamide
gels.
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HMG2L1 5’-CTCCACACAGATGGGCATAG 5’-CCCCCACCACACTTAAAAGA 103
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